Revenue exceeds Wall Street consensus estimate of $4.37 million
Gross Profit More Than Seven Times Prior Year • Operating Loss Narrows 35% • Adjusted EBITDA Loss Narrows 64%
MCLEAN, Va., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Cycurion, Inc. (NASDAQ: CYCU) ("Cycurion" or the "Company"), a predictive cybersecurity company delivering AI-driven cybersecurity, national security, and public safety technology solutions, today announced its financial results for the third quarter ended September 30, 2026. The Company reported higher revenue and gross profit, with contributions from acquired businesses and a return to growth in existing operations.
Third Quarter 2026 Highlights
Management Commentary
"Our third-quarter results demonstrate the momentum we are building at Cycurion," said L. Kevin Kelly, Chairman and Chief Executive Officer. "Higher-margin revenue translated into substantially more gross profit, and we narrowed our operating and adjusted EBITDA losses. We also returned to revenue growth in our existing operations while adding contributions from our acquisitions. We are encouraged by this progress and focused on carrying it forward."
"We see a significant opportunity ahead. Our acquisitions have expanded our capabilities and customer reach, and our predictive intelligence strategy gives us more ways to help customers identify and address their most consequential threats. Our team, which includes veterans of the U.S. Intelligence Community and the private-sector cybersecurity industry, is focused on converting those opportunities into recurring revenue, stronger gross profit and continued progress toward profitability. We are building on a stronger operating foundation while maintaining expense discipline and working to improve operating cash flow."
Strategic and Operational Progress
Additional Financial Information
The third quarter 2026 delivered record revenue and gross profit results, higher gross margin and narrower net and adjusted EBITDA losses with higher margin acquisitions and organic growth driving these results.
The Company's reported net loss was $3.1 million, compared to $3.2 million in the prior year quarter. The prior-year quarter's net loss benefited from a one-time $2.0 million gain on debt settlement. Excluding that non-recurring gain from the prior year comparison, net loss improved 41% year-over-year. To give a clearer view of underlying operating performance, we also evaluate results using EBITDA and Adjusted EBITDA, which are non-GAAP measures. Reconciliations of net loss to EBITDA and Adjusted EBITDA are included in the financial schedules accompanying this release.
Net loss attributable to Cycurion was $2.9 million, or $1.03 per basic and diluted share, compared to $3.1 million, or $12.39 per basic share and $12.36 per diluted share in the prior-year quarter. Per-share amounts reflect the 1-for-8 reverse stock split effective August 28, 2026, applied retroactively to all periods presented.
Nine-Month 2026 Results
For the nine months ended September 30, 2026, revenue increased 7% to $12.4 million from $11.6 million, compared to the prior year period. Gross profit more than tripled to $3.7 million from $1.2 million in the prior year period, and gross margin expanded to 30% from 10%. Net loss improved 48% to $9.7 million from $18.8 million in the prior year period.
Adjusted EBITDA loss was $4.6 million, compared to $4.1 million in the prior year period, reflecting public-company costs, SLG Innovation, Inc. consolidation, key growth hires and the two 2026 acquisitions of Secuvant and Cycurion Digital Ally, partly offset by third-quarter revenue growth and improved gross margin.
Balance Sheet and Liquidity
As of September 30, 2026, cash and cash equivalents were $3.0 million, compared to $1.9 million as of June 30, 2026, and $3.7 million as of September 30, 2025. During the quarter, the Company raised $4.5 million in gross proceeds through a warrant inducement transaction with an existing investor. It used $1.5 million of those proceeds to fund acquisitions and the remainder to support working capital needs.
Net debt, a non-GAAP measure, was $5.3 million, compared to $5.2 million as of September 30, 2025, and $2.8 million as of December 31, 2025. The increase reflects a $4.3 million promissory note issued for the acquisition of Kustom's video solutions business, partially offset by conversions of a substantial portion of other notes into common stock during the months of July and August of 2026.
As disclosed in the Company's Quarterly Report on Form 10-Q, we continue to face going concern uncertainty. We ended the quarter with a working capital deficit of $10.5 million, up from $8.9 million as of December 31, 2025, driven mainly by the promissory note for the Cycurion Digital Ally acquisition and higher accounts payable tied to growth and public-company costs. Third-quarter revenue growth, improved gross margin, lower debt following note conversions and higher receivables and inventory partially offset the increase.
Outlook
Cycurion enters the fourth quarter with momentum, focused on building on its operating improvement. Work under the state health and human services contract is expected to begin at the end of the first quarter of 2027. Habit’s launch creates an additional commercialization opportunity. Management’s priorities are to integrate acquired operations, expand higher-margin recurring services and pursue cross-selling across the customer base while maintaining expense discipline. The objective is to grow gross profit faster than operating costs, continue narrowing losses and improve operating cash flow. The Company does not provide quarterly financial guidance.
Earnings Call
Cycurion will host an earnings call today, Monday, November 16, 2026, at 9:30 a.m. Eastern Time. Management will deliver prepared remarks and respond to questions that were submitted in advance. To view the live webcast, please register at https://edge.media-server.com/mmc/p/e3ncvmao. A replay and transcript will be available on the Company’s investor relations page at https://investors.cycurion.com/investor-faq following the call.
About Cycurion, Inc.
Based in McLean, Virginia, Cycurion (NASDAQ: CYCU) is a forward-thinking provider of IT cybersecurity solutions and AI, committed to delivering secure, reliable, and innovative services to clients worldwide. Specializing in cybersecurity, program management, and business continuity, Cycurion harnesses its expert team to empower clients and safeguard their operations. Along with its subsidiaries, Axxum Technologies LLC, Cloudburst Security LLC, Secuvant LLC, Cycurion Digital Ally Inc. and Cycurion Innovation, Inc., Cycurion serves government, healthcare, and corporate clients committed to securing the digital future. For more information, visit www.cycurion.com.
Forward-Looking Statements
Certain statements in this press release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements contained in this press release that are not statements of historical fact may be deemed forward-looking statements. This cautionary statement also applies to forward-looking statements made by management during the Company’s earnings call to be held on November 16, 2026. Such statements include, but are not limited to, statements regarding the integration and expected contributions of acquired businesses, including Secuvant and Cycurion Digital Ally; opportunities to cross-sell services to existing and acquired customers, including public safety organizations; the adoption and commercialization of Habit and the execution of the Company’s predictive cybersecurity strategy; the acceleration of the Company’s inorganic growth strategy through potential acquisitions and strategic transactions; the continued execution of the Company’s contracted backlog; the commencement, ramp, timing, amount and likelihood of realizing revenues associated with our contracted backlog, including the Company’s 10-year state health and human services award; the Company’s objectives to grow recurring revenue and gross profit, narrow losses, improve operating cash flow and progress toward profitability; and other statements that are not historical facts, including statements which may be accompanied by words such as “continue,” “will,” “may,” “could,” “should,” “expect,” “expected,” “plans,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “objective,” “opportunity,” and similar expressions intended to identify such forward-looking statements. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, many of which are generally outside the control of Cycurion and are difficult to predict. Examples of such risks and uncertainties include, but are not limited to, risks related to the Company’s ability to continue as a going concern, its working capital deficit and its ability to obtain financing on acceptable terms or at all, including potential dilution to stockholders; the Company’s indebtedness, including the promissory note issued in connection with the acquisition of Kustom Entertainment Inc.’s video solutions business; the Company’s ability to successfully integrate acquired businesses and realize their anticipated benefits; market acceptance of new offerings, including Habit; risks inherent in government contracting, including funding and appropriations and the possibility that award values are not fully realized; competition; the Company’s ability to maintain the listing of its common stock on Nasdaq; customer performance and satisfaction, contract modifications, delays or terminations, and the Company’s ability to fulfill contractual obligations, the outcomes of the Company’s investigations, any potential legal proceedings, or the future performance of the Company’s stock. Additional factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements can be found in the most recent annual report on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K filed by Cycurion with the U.S. Securities and Exchange Commission, including the risk factors and going-concern disclosures in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026. Cycurion anticipates that subsequent events and developments may cause its plans, intentions, and expectations to change. Cycurion assumes no obligation, and it specifically disclaims any intention or obligation, to update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as expressly required by law. Forward-looking statements speak only as of the date they are made and should not be relied upon as representing Cycurion’s plans and expectations as of any subsequent date.
Non-GAAP Financial Measures
This release includes non-GAAP financial measures (EBITDA and Adjusted EBITDA). These measures are provided for supplemental informational purposes only and should not be considered substitutes for GAAP results. A reconciliation of net loss to EBITDA and Adjusted EBITDA is included in the Company’s full earnings materials filed with the SEC.
In addition to our results determined in accordance with U.S. GAAP, we believe the non-GAAP financial measures of EBITDA, and Adjusted EBITDA are useful in evaluating our operating performance. We believe that this non-GAAP financial information, when taken collectively with our GAAP results, may be helpful to readers of our financial statements because it provides consistency and comparability with past financial performance and assists in comparisons with other companies, some of which use similar non-GAAP financial information to supplement their GAAP results. The non-GAAP financial information is presented for supplemental informational purposes only, should not be considered a substitute for financial information presented in accordance with GAAP, and may be different from similarly-titled non-GAAP measures used by other companies. A reconciliation is provided below for each of these non-GAAP financial measures to the most directly comparable financial measure stated in accordance with GAAP. Cycurion believes that EBITDA and Adjusted EBITDA provide the Board of Directors, management and investors with a clear representation of the Company's core operating performance and trends, provide greater visibility into the long-term financial performance of the Company, and eliminate the impact of items that do not relate to the ongoing operating performance of the business. Cycurion believes these non-GAAP financial measures facilitate the comparison of the Company's operating performance on a consistent basis between periods by excluding certain items that may, or could, have a disproportionately positive or negative impact on the Company's results of operations in any particular period. When viewed in combination with the Company's results prepared in accordance with GAAP, these non-GAAP financial measures help provide a broader picture of factors and trends affecting the Company's results of operations. EBITDA and Adjusted EBITDA are supplemental measures of operating performance that are not made under GAAP and do not represent, and should not be considered as an alternative to net (loss)/income, earnings per share or operating expenses, as determined by GAAP. The Company defines EBITDA as net (loss)/income, adjusted for interest expense, provision for/(benefit from) income taxes, and depreciation and amortization. The Company defines Adjusted EBITDA as EBITDA, adjusted for stock-based compensation expense, gain/(loss) on debt settlement, acquisition and transaction costs and other one-time expenses that are not part of the normal operating activities.
EBITDA and Adjusted EBITDA each has limitations as an analytical tool, and you should not consider any of them in isolation, or as a substitute for analysis of results as reported under GAAP. Other companies in the Company's industry may calculate Adjusted EBITDA differently than Cycurion does, which limits its usefulness as a comparative measure. Because of these limitations, neither EBITDA or Adjusted EBITDA should be considered as a replacement for net (loss)/income, or as a measure of profitability. Cycurion compensates for these limitations by relying primarily on the Company’s GAAP results and using non-GAAP measures only for supplemental purposes.
Cycurion Investor Relations:
(888) 341-6680
investors@cycurion.com
Cycurion Media Relations:
(888) 341-6680
media@cycurion.com
| Non-GAAP Financial Measures | |||||||||||||||
| (Unaudited) | |||||||||||||||
| Reconciliation of Net Loss to EBITDA (Non-GAAP) and Adjusted EBITDA (Non-GAAP) | |||||||||||||||
| For the Three Months Ended September 30, | For the Nine Months Ended September 30, | ||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||
| Net Loss | $ | (3,125,085 | ) | $ | (3,240,017 | ) | $ | (9,726,438 | ) | $ | (18,778,917 | ) | |||
| Interest income | (21,555 | ) | (1,770 | ) | (39,297 | ) | (1,770 | ) | |||||||
| Interest expense | 179,819 | 712,374 | 612,612 | 1,506,657 | |||||||||||
| Depreciation and amortization | — | 24,749 | — | 45,321 | |||||||||||
| EBITDA (Non-GAAP) | (2,966,821 | ) | (2,504,664 | ) | (9,153,123 | ) | (17,228,709 | ) | |||||||
| (Gain)/loss on debt settlement, net (1) | — | (2,016,469 | ) | 1,930,427 | (1,250,139 | ) | |||||||||
| Transaction related expenses (2) | 28,500 | (874,008 | ) | 103,737 | 11,240,114 | ||||||||||
| One-time expenses (3) | 63,000 | — | 153,000 | — | |||||||||||
| Stock compensation expenses (4) | 1,687,250 | 2,082,000 | 2,339,805 | 3,094,443 | |||||||||||
| Adjusted EBITDA (Non-GAAP) | $ | (1,188,071 | ) | $ | (3,313,141 | ) | $ | (4,626,154 | ) | $ | (4,144,291 | ) | |||
| (1) | (Gain)/loss on debt settlement, net represents the conversion of the promissory notes primarily related to the deemed issuance cost of preferred stock issued to satisfy default interest obligations. |
| (2) | Acquisition and transaction/business combination costs generally represent professional fees and direct expenses related to acquisitions and public offerings. |
| (3) | One-time expenses represent non-ordinary course costs in connection with a change in a contract or a change in the makeup of our personnel often related to an acquisition, such as severance payments, recruiting fees and retention charges. |
| (4) | Stock compensation expense represents a portion of compensation paid to our employees and executives through stock-based instruments. |
| CYCURION, INC. AND SUBSIDIARIES | |||||||||||||||
| CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS | |||||||||||||||
| (Unaudited) | |||||||||||||||
| For the Three Months Ended September 30, | For the Nine Months Ended September 30, | ||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||
| Revenue | $ | 5,378,452 | $ | 3,833,038 | $ | 12,404,148 | $ | 11,591,003 | |||||||
| Cost of revenue | 3,454,160 | 3,562,559 | 8,698,161 | 10,406,824 | |||||||||||
| Gross profit | 1,924,292 | 270,479 | 3,705,987 | 1,184,179 | |||||||||||
| Operating expenses: | |||||||||||||||
| Selling, general and administrative expenses | 3,203,863 | 2,719,600 | 8,588,878 | 5,244,323 | |||||||||||
| Stock compensation expenses | 1,687,250 | 2,082,000 | 2,339,805 | 3,094,443 | |||||||||||
| Business combination expenses | — | — | — | 11,240,114 | |||||||||||
| Total operating expenses | 4,891,113 | 4,801,600 | 10,928,683 | 19,578,880 | |||||||||||
| Operating loss | (2,966,821 | ) | (4,531,121 | ) | (7,222,696 | ) | (18,394,701 | ) | |||||||
| Other income/(expenses): | |||||||||||||||
| Interest income | 21,555 | 1,770 | 39,297 | 1,770 | |||||||||||
| Interest expense | (179,819 | ) | (712,374 | ) | (612,612 | ) | (1,506,657 | ) | |||||||
| Gain/(loss) on debt settlement, net | — | 2,016,469 | (1,930,427 | ) | 1,250,139 | ||||||||||
| Other expense, net | — | (14,761 | ) | — | (129,468 | ) | |||||||||
| Other (expenses)/income, net | (158,264 | ) | 1,291,104 | (2,503,742 | ) | (384,216 | ) | ||||||||
| Loss before income taxes | (3,125,085 | ) | (3,240,017 | ) | (9,726,438 | ) | (18,778,917 | ) | |||||||
| Provision for income tax | — | — | — | — | |||||||||||
| Net loss | (3,125,085 | ) | (3,240,017 | ) | (9,726,438 | ) | (18,778,917 | ) | |||||||
| Less: Net loss attributable to non-controlling interest | 202,238 | 116,700 | 919,355 | 218,359 | |||||||||||
| Net loss attributable to Cycurion | $ | (2,922,847 | ) | $ | (3,123,317 | ) | $ | (8,807,083 | ) | $ | (18,560,558 | ) | |||
| Comprehensive loss | $ | (2,922,847 | ) | $ | (3,123,317 | ) | $ | (8,807,083 | ) | $ | (18,560,558 | ) | |||
| Loss per share: | |||||||||||||||
| Basic | $ | (1.03 | ) | $ | (12.39 | ) | $ | (5.80 | ) | $ | (114.40 | ) | |||
| Diluted | $ | (1.03 | ) | $ | (12.36 | ) | $ | (5.80 | ) | $ | (113.85 | ) | |||
| Weighted average shares outstanding: | |||||||||||||||
| Basic | 2,826,145 | 252,053 | 1,518,128 | 162,247 | |||||||||||
| Diluted | 2,826,145 | 252,473 | 1,518,128 | 162,667 | |||||||||||
| CYCURION, INC. AND SUBSIDIARIES | |||||||
| CONSOLIDATED BALANCE SHEETS | |||||||
| (Unaudited) | |||||||
| September 30, 2026 | December 31, 2025 | ||||||
| Assets: | |||||||
| Cash and cash equivalents | $ | 2,982,927 | $ | 5,255,235 | |||
| Accounts receivable, net | 4,003,712 | 2,687,479 | |||||
| Prepaid expenses and other current assets | 330,712 | 60,133 | |||||
| Inventory | 1,756,642 | — | |||||
| Other receivables | — | — | |||||
| Total current assets | 9,073,993 | 8,002,847 | |||||
| Software development costs, net | 4,891,981 | 4,606,981 | |||||
| Goodwill and intangibles | 33,537,443 | 20,842,508 | |||||
| Other assets - non-current | 491,044 | — | |||||
| Total non-current assets | 38,920,468 | 25,449,489 | |||||
| Total assets | $ | 47,994,461 | $ | 33,452,336 | |||
| Liabilities and Stockholders' Equity: | |||||||
| Liabilities: | |||||||
| Bank loan-revolving credit line | $ | 2,421,305 | $ | 2,933,396 | |||
| Loans payable - current portion | 269,068 | 669,693 | |||||
| Factoring liability | 985,214 | 1,511,678 | |||||
| Convertible notes | 76,609 | 192,897 | |||||
| Promissory notes | 2,419,812 | 2,499,662 | |||||
| Loans payable - related parties | — | 123,650 | |||||
| Accounts payable | 1,476,357 | 1,314,772 | |||||
| Accrued liabilities | 8,015,096 | 4,228,337 | |||||
| Accrued compensation and benefits | 1,413,471 | 919,825 | |||||
| Contract liabilities - current portion | 1,015,130 | — | |||||
| Accrued interest payable | 278,001 | 1,347,787 | |||||
| Excise tax payable | 1,167,173 | 1,167,173 | |||||
| Total current liabilities | 19,537,236 | 16,908,870 | |||||
| Contract liabilities - non-current portion | 1,237,191 | — | |||||
| Loans payable - non-current portion | 2,815,394 | 300,000 | |||||
| Total non-current liabilities | 4,052,585 | 300,000 | |||||
| Total liabilities | 23,589,821 | 17,208,870 | |||||
| Stockholders' Equity: | |||||||
| Preferred stock ($0.0001 par value, 20,000,000 shares authorized) | |||||||
| Series A convertible preferred stock ($0.0001 par value, 110,000 shares designated, 0 and 0 issued and outstanding, respectively) | — | — | |||||
| Series B convertible preferred stock ($0.0001 par value, 3,000 shares designated, 0 and 1 issued and outstanding, respectively) | — | — | |||||
| Series C convertible preferred stock ($0.0001 par value, 5,000 shares designated, 2,547 and 4,851 issued and outstanding, respectively) | — | — | |||||
| Series D convertible preferred stock ($0.0001 par value, 6,666,700 shares designated, 150,000 and 150,000 issued and outstanding, respectively) | 15 | 15 | |||||
| Series E convertible preferred stock ($0.0001 par value, 100 shares designated, 51 and 51 issued and outstanding, respectively) | — | — | |||||
| Series F convertible preferred stock ($0.0001 par value, 10,000 shares designated, 0 and 0 issued and outstanding, respectively) | — | — | |||||
| Series G convertible preferred stock ($0.0001 par value, 10,000 shares designated, 143 and 143 issued and outstanding, respectively) | — | — | |||||
| Series H convertible preferred stock ($0.0001 par value, 10,000 shares designated, 2,172 and 0 issued and outstanding, respectively) | — | — | |||||
| Series I convertible preferred stock ($0.0001 par value, 888,888 shares designated, 888,888 and 0 issued and outstanding, respectively) | 89 | — | |||||
| Common stock ($0.0001 par value, 300,000,000 shares authorized, 3,620,618 and 455,308 shares issued and outstanding, respectively) | 362 | 46 | |||||
| Additional paid in capital | 64,867,287 | 46,980,080 | |||||
| Accumulated deficit | (35,686,164 | ) | (26,879,081 | ) | |||
| Total stockholders' equity attributable to Cycurion | 29,181,589 | 20,101,060 | |||||
| Deficit attributable to noncontrolling interests | (4,776,949 | ) | (3,857,594 | ) | |||
| Total stockholders' equity | 24,404,640 | 16,243,466 | |||||
| Total liabilities and stockholders’ equity | $ | 47,994,461 | $ | 33,452,336 | |||
| CYCURION, INC. AND SUBSIDIARIES | |||||||
| CONSOLIDATED STATEMENTS OF CASH FLOWS | |||||||
| (Unaudited) | |||||||
| For the Nine Months Ended September 30, | |||||||
| 2026 | 2025 | ||||||
| Cash flows from operating activities: | |||||||
| Net loss | $ | (9,726,438 | ) | $ | (18,778,917 | ) | |
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||||
| Stock compensation expenses | 2,339,805 | 3,094,443 | |||||
| Stock-based compensation - business combination related | - | 9,521,734 | |||||
| Amortization of debt discount | 1,187 | 234,430 | |||||
| Recovery of credit losses | (130,365 | ) | - | ||||
| Depreciation of property and equipment | - | 20,321 | |||||
| Amortization of software costs | - | 25,000 | |||||
| Loss/(gain) on debt settlement, net | 1,930,427 | (1,250,139 | ) | ||||
| Finance expense | - | 100,000 | |||||
| Changes in assets and liabilities: | |||||||
| Accounts receivable, net and other receivables | (242,908 | ) | (286,701 | ) | |||
| Prepaid expenses and other current assets | (152,486 | ) | 42,326 | ||||
| Accounts payable and accrued liabilities | (1,698,365 | ) | (1,524,012 | ) | |||
| Accrued compensation and benefits | (212,795 | ) | 104,518 | ||||
| Contract assets and liabilities, net | (204,291 | ) | - | ||||
| Accrued interest payable | 286,848 | (74,922 | ) | ||||
| Net cash used in operating activities | (7,809,381 | ) | (8,771,919 | ) | |||
| Cash flows from investing activities: | |||||||
| Net cash disbursed on business combinations | (1,566,986 | ) | 34,983 | ||||
| Capitalized software development costs | (285,000 | ) | (268,000 | ) | |||
| Cash withdrawn from Trust Account in connection with redemption | - | 1,001,216 | |||||
| Release of Trust Account to Company's bank account | - | 833,324 | |||||
| Net cash (used in)/provided by investing activities | (1,851,986 | ) | 1,601,523 | ||||
| Cash flows from financing activities: | |||||||
| Proceeds from exercise of warrants, net | 3,845,453 | 3,664,871 | |||||
| Redemption of common stock subject to redemption | - | (1,001,216 | ) | ||||
| Proceeds from capital raise | 4,067,728 | 5,874,584 | |||||
| Repayments of revolving line of credit | (512,091 | ) | (18,000 | ) | |||
| Repayment of bank borrowings | - | (499,180 | ) | ||||
| Proceeds from convertible notes payable | - | 2,376,500 | |||||
| Proceeds from notes payable | - | 513,200 | |||||
| Repayments of notes payable | (12,031 | ) | (101,579 | ) | |||
| Net cash provided by financing activities | 7,389,059 | 10,809,180 | |||||
| Net (decrease)/increase in cash and cash equivalents | (2,272,308 | ) | 3,638,784 | ||||
| Cash and cash equivalents, beginning of period | 5,255,235 | 40,790 | |||||
| Cash and cash equivalents, end of period | $ | 2,982,927 | $ | 3,679,574 | |||